Loading...
Market
How many countries will approve Pfizer's gene therapy for Hemophilia A by December 31, 2025?
2
Resolution / Starting Odds
<10 countries • 25%
10-20 countries • 25%
20-30 countries • 25%
>30 countries • 25%
Official announcements from health regulatory agencies
Story
Pfizer's $PFE Gene Therapy Shows Positive Results in Hemophilia A Late-Stage Phase 3 Study
Jul 24, 2024, 10:49 AM
Pfizer has announced positive topline results from its Phase 3 study of a gene therapy candidate for Hemophilia A. The therapy, developed in collaboration with Sangamo Therapeutics, aims to reduce bleeding episodes in patients with the severe bleeding disorder. The study's success marks a significant milestone in the treatment of Hemophilia A, offering hope for improved management of the condition. Pfizer's stock symbol is $PFE, and the therapy met its goal in a pivotal late-stage trial.
View original story
Similar markets
Less than 1,000 • 25%
1,000 to 5,000 • 25%
5,000 to 10,000 • 25%
More than 10,000 • 25%
Yes • 50%
No • 50%
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
0-10 countries • 25%
11-20 countries • 25%
21-30 countries • 25%
31 or more countries • 25%
1-3 countries • 25%
4-6 countries • 25%
7-9 countries • 25%
10 or more countries • 25%
Less than 10 • 25%
10 to 20 • 25%
20 to 30 • 25%
More than 30 • 25%
0 • 25%
1-2 • 25%
3-4 • 25%
5 or more • 25%